key: cord-0761625-uo5jmixg authors: Mitamura, Yasutaka; Schulz, Daniel; Oro, Saskia; Li, Nick; Kolm, Isabel; Lang, Claudia; Ziadlou, Reihane; Tan, Ge; Bodenmiller, Bernd; Steiger, Peter; Marzano, Angelo; de Prost, Nicolas; Caudin, Olivier; Levesque, Mitchell; Stoffel, Corinne; Schmid‐Grendelmeier, Peter; Maverakis, Emanual; Akdis, Cezmi A.; Brüggen, Marie‐Charlotte title: Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients date: 2021-07-19 journal: Allergy DOI: 10.1111/all.14983 sha: 2732b6d9cd387ded1e4c47aeb8117d4165e952f3 doc_id: 761625 cord_uid: uo5jmixg BACKGROUND: Coronavirus disease‐2019 (COVID‐19) has been associated with cutaneous findings, some being the result of drug hypersensitivity reactions such as maculopapular drug rashes (MDR). The aim of this study was to investigate whether COVID‐19 may impact the development of the MDR. METHODS: Blood and skin samples from COVID‐19 patients (based on a positive nasopharyngeal PCR) suffering from MDR (COVID‐MDR), healthy controls, non‐COVID‐19—related patients with drug rash with eosinophilia and systemic symptoms (DRESS), and MDR were analyzed. We utilized imaging mass cytometry (IMC) to characterize the cellular infiltrate in skin biopsies. Furthermore, RNA sequencing transcriptome of skin biopsy samples and high‐throughput multiplexed proteomic profiling of serum were performed. RESULTS: IMC revealed by clustering analyses a more prominent, phenotypically shifted cytotoxic CD8(+) T cell population and highly activated monocyte/macrophage (Mo/Mac) clusters in COVID‐MDR. The RNA sequencing transcriptome demonstrated a more robust cytotoxic response in COVID‐MDR skin. However, severe acute respiratory syndrome coronavirus 2 was not detected in skin biopsies at the time point of MDR diagnosis. Serum proteomic profiling of COVID‐MDR patients revealed upregulation of various inflammatory mediators (IL‐4, IL‐5, IL‐6, TNF, and IFN‐γ), eosinophil and Mo/Mac ‐attracting chemokines (MCP‐2, MCP‐3, MCP‐4 and CCL11). Proteomics analyses demonstrated a massive systemic cytokine storm in COVID‐MDR compared with the relatively milder cytokine storm observed in DRESS, while MDR did not exhibit such features. CONCLUSION: A systemic cytokine storm may promote activation of Mo/Mac and cytotoxic CD8(+) T cells in severe COVID‐19 patients, which in turn may impact the development of MDR. Delayed-type drug hypersensitivity reactions (DDH) result from T cell-mediated immune responses against drugs (Gell and Coombs type IV allergic reaction). 1 DDH affect about 7% of the general population. 2, 3 The most common DDH are maculopapular drug exanthemas (maculopapular drug rashes; MDR), which are typically mild reactions that are limited to the skin and controllable with topical corticosteroids. 4 In contrast, severe cutaneous hypersensitivity reactions are rare, but life-threatening when they occur. Drug reaction with eosinophilia and systemic symptoms (DRESS) belongs to the category of severe DDH. 5 Since the beginning of the Coronavirus disease 19 pandemic, 6 different types of DDH have been reported in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients, 7 raising the question as to how COVID-19 is associated with their development. We and others have reported glucocorticoidrefractory severe DRESS with massive eosinophilia in COVID-19 patients. 8, 9 Besides DDH, other cutaneous eruptions have been associated with SARS-CoV-2 infection and have been observed in approximately 1-20% of the patients. [10] [11] [12] [13] [14] [15] These various skin manifestations of SARS-CoV-2 infection 16, 17 may be due in part to the SARS-CoV-2 spike protein receptor (angiotensin-converting enzyme 2, ACE2) being expressed by keratinocytes. 17 Supporting this possibility is the finding that SARS-CoV-2 RNA can be directly isolated from the skin of some COVID-19 patients. 18 Here we report a series of MDR cases in severely ill patients and sought to address how MDR occurring in COVID-19 patients (COVID-MDR) differs from MDR not related to COVID, and DRESS. Marie-Charlotte Brüggen, Department of Dermatology, Allergy Unit, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland. Email: marie-charlotte.brueggen@usz.ch We wanted to explore whether severe COVID-19 may impact the development of maculopapular drug rashes (MDR). Study Design: we collected clinical data, skin and blood specimens of COVID-MDR, MDR-and DRESS-patients as well as HC and explored their cellular and molecular immune signatures. This revealed a distinct signature of COVID-MDR both on a cutaneous and skin elvel: In the skin (upper right case), we found by imaging mass cytometry in COVID-MDR highly activated monocyte/macrophages as well as phenotypically shifted CD8+ T cells, paralleled by a robust cytotoxic signature on an mRNA level. This was paralleled by a massive cytokine storm in the peripheral blood, which, to a lesser extent, was also present in DRESS (lower left case). Our findings suggest, that the cytokine storm in severe course of COVID-19 may promote hyperactivation of cytotoxic T cells and monocytes, which in turn are involved in MDR development. We included all cases of COVID-MDR (n = 12) treated in the inten- identification of a culprit drug ( All blood and skin samples were taken on the day of symptom onset, that is, prior the initiation of any treatment. Skin punch biopsies were taken from all patients for histopathological evaluation Skin samples were formalin-fixed and paraffin-embedded (FFPE). Blood samples were obtained COVID-MDR, COVID w/o MDR, DRESS, MDR patients and HC (n = 5 each). Blood, collected using serum tubes, was processed immediately after collection and stored at −80°C until further processing. All antibodies used for IMC were titrated and validated by immunofluorescence for specific staining patterns and in IMC for co-staining with other known markers. Some antibodies were additionally tested with an antigen-binding fragment (Fab) labelling kit, used as previously described. 19 We designed an IMC panel consisting of 36 antibodies covering both non-leukocytic and leukocytic, mostly T cell-and antigen-presenting cell-related, antigens (Table 2) . We Pre-processing and single-cell segmentation were performed following the instructions on the Bodenmiller Github repository (https:// github.com/Boden mille rGrou p/ImcSe gment ation Pipeline). After single-cell generation, all subsequent analyses were performed using R bioconductor. For cell-type annotation, we manually gated major cell types of interest using the cytomapper R package. 20 The following markers were used to define cell types: CD8 + (Table S2 ). All RNA-seq data performed in this paper can be found on the NCBI Gene Expression Omnibus (GEO) under accession number GSE161225. Enrichr, a gene list enrichment analysis tool, was utilized to search for enriched Gene ontology biological processes (GO BP). The data of a proteomic multiplex assay in Normalized protein expression (NPX) format were imported, processed by Olink-R Package age was 55 ± 7 years. In all patients, 50-80% of the body surface area was affected ( Figure 1A) . A prominent eosinophilia (median: 940/mm 3 ; range 400-6000) was present in all patients, which was more than in non COVID-19-related MDR ( Figure S1A ) We first investigated the histopathological features of COVID-MDR. To analyze the T cell compartment in more detail, we sub-clustered Figure 3A ,B, Figure S3A ). Among CD8 + T cells, the most proliferative and cytotoxic cluster IV was increased in COVID-MDR. These cells showed strong expression of Ki67, GrzB, CD16 and the co-stimulation/ activation marker CD27. Separation of CD8 + T cells by indication confirmed that CD8 + COVID-MDR T cells exhibit a more cytotoxic phenotype in comparison to MDR and DRESS ( Figure 2E and Figure S3A ). All DDH showed elevated levels of CLA − CD8 + T cells, indicating an influx of non-resident T cells into the skin. In contrast to CD8 + T cells, there were no major differences in the numbers of CD4 + T cell clusters between the different DDH. It can, however, be observed that cluster III CD4 + T cells were increased in all DDH, while cluster IV CD4 + T cells were slightly increased in MDR only. Foxp3-positive CD4 + T cells (cluster I) were even slightly more prominent in HC as compared to the DDH. Of note, in some T cell clusters and especially in COVID-MDR, we observed the expression of certain myeloid markers (CD1c, CD11c, CD40, CD163), and CD8 + T cells showed a certain expression level of CD4 ( Figure 3B ). These signals are most likely observed due to low resolution of our images and the limits of cellular segmentation. Thus one can assume that CD8 + T cells that express CD4 or myeloid markers are in spatial proximity to myeloid cells which may be the cells that actually activate the T cells. We investigated the cellular contacts amount the cell types classified in this dataset and compared them to HC samples ( Figure 3E ). Overall, the patterns of interaction between the indications were very similar. Despite the large differences in interaction counts, we did not observe interactions that were absent in any of the indications while present in another. We also applied our previously published neighborhood algorithm and could not detect recurrent significant changes (data not shown). We conclude that the overall cellular interactions in drug rashes stay intact given that larger amounts of immune cells are present. Our IMC data showed a distinct CD8 The distinct cellular and molecular signature in COVID-MDR sug- Figure S2 ). On the gene expression level, however, ACE2 but not other receptor-related molecules were upregulated in COVID MDR, and, to a lesser extent also in MDR as compared to HC ( Figure 4D , Figure S5 ). The absence of viral RNA in the skin suggested that a massive systemic inflammatory response rather than SARS-CoV-2 in the skin By IMC, prominent CD8 + T cell infiltrates and highly activated Mo/Mac clusters were characteristic of COVID-MDR. Interestingly, a recent paper has identified dysfunctional HLA-DR low CD163 high and HLA-DR low S100A high CD14 + Mo in the blood of severely affected We thank Anja Heider for her help in the laboratory and Anna Głobińska for her help to prepare the graphical abstract. We thank Yi Xiao and M. Milad Ameri for their help in the statistical analysis. We thank Nils Eling of the Bodenmiller lab for his implementation of the cell-type classification. CA reports grants from Allergopharma, Idorsia, Swiss National Science Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice International consensus on drug allergy Selfreported drug allergy in a general adult Portuguese population Spontaneous cutaneous adverse drug reaction reports -an analysis of a 10-year dataset in Singapore Drug reaction with eosinophilia and systemic symptoms (DReSS): how far have we come? A novel coronavirus from patients with pneumonia in China A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? Benralizumab for severe DRESS in two COVID-19 patients Detection of SARS-CoV-2 in a case of DRESS by sulfasalazine: could there be a relationship with clinical importance? Emerging treatments in COVID-19: adverse drug reactions including drug hypersensitivities SARS-CoV-2, COVID-19, skin and immunology -what do we know so far? Comment on 'Cutaneous manifestations in COVID-19: a first perspective' by Recalcati S Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases A compendium answering 150 questions on COVID-19 and SARS-CoV-2 Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 High expression of ACE2 on keratinocytes reveals skin as a potential target for SARS-CoV-2 SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report Subcutaneous white adipose tissue of healthy young individuals harbors a leukocyte compartment distinct from skin and blood cytomapper: an R/ Bioconductor package for visualisation of highly multiplexed imaging data Building predictive models in R using the caret package histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli Evidence for different immune signatures and sensitization patterns in sub-Saharan versus central European Atopic Dermatitis patients SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors Immunology of COVID-19: mechanisms, clinical outcome, diagnostics, and perspectives-a report of the European Academy of Allergy and Clinical Immunology (EAACI) Genderbased differences by age range in patients hospitalized with COVID-19: a Spanish observational cohort study Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Is a "cytokine storm" relevant to COVID-19? Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study COVID-19: in the eye of the cytokine storm Clinical and immunological features of severe and moderate coronavirus disease 2019 Clinical characteristics of coronavirus disease 2019 in China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19 Single-cell landscape of immunological responses in patients with COVID-19 Severe COVID-19 is marked by a dysregulated myeloid cell compartment Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment Assessment of drug causality in Stevens-Johnson syndrome/toxic epidermal necrolysis: concordance between lymphocyte transformation test and ALDEN Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response Overexpression of cytotoxic proteins correlates with liver function impairment in patients with drug reaction with eosinophilia and systemic symptoms (DRESS) Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Comparative histological analysis of drug-induced maculopapular exanthema and DRESS Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions